Table 1.
Characteristics of rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis patients.
| All groups (n = 459) | Rheumatoid arthritis (n = 204) | Spondyloarthritis (n = 200) | Psoriatic arthritis (n = 55) | p: RA vs. SpA vs. PsA | |
|---|---|---|---|---|---|
| Female, n (%) | 335 (73.0) | 166 (81.4) | 124 (62.0) | 45 (81.8) | <0.001 |
| Age at diagnosis * | 44 (14–88) | 50 (41–60) | 38 (32–47) | 45 (35–52) | <0.001 |
| Duration of disease at the time of CT/MRI * | 4 (−7 to 39) | 5 (−5 to 39) | 4 (−4 to 35) | 2 (−7 to 35) | 0.046 |
| Reason for imaging, n (%) | 0.10 | ||||
| Suspicion of disease involvement | 90 (19.6) | 30 (14.7) | 43 (21.5) | 17 (30.9) | |
| Head and neck pain | 141 (30.7) | 61 (29.9) | 70 (35) | 10 (18.2) | |
| Discopathy–radiculopathy | 131 (28.5) | 68 (33.3) | 47 (23.5) | 16 (29.1) | |
| Trauma | 41 (8.9) | 17 (8.3) | 19 (9.5) | 5 (9.1) | |
| Other/unknown | 56 (12.2) | 28 (13.7) | 21 (10.5) | 7 (12.7) | |
| Comorbidity, n (%) | 0.52 | ||||
| DM | 80/458 (17.5) | 46/203 (22.7) | 20/199 (10.1) | 14 (25.5) | |
| HT | 159/458 (34.7) | 93 (45.6) | 46/199 (23.1) | 20 (36.4) | |
| HL | 74/458 (16.2) | 35 (17.2) | 31/199 (15.7) | 8 (14.5) | |
| CKD | 13/458 (2.8) | 9 (4.4) | 3/199 (1.5) | 1 (1.8) | |
| Malignancy | 20/458 (4.4) | 14 (6.9) | 5/199 (2.5) | 1 (1.8) | |
| Other | 253/458 (55.4) | 91 (44.6) | 133/199 (67.2) | 29 (52.7) | |
| Smoking, n (%) | 0.007 | ||||
| Never smoked | 126 (27.5) | 62 (30.4) | 54 (27.0) | 10 (18.2) | |
| Active or former smoker | 158 (34.4) | 53 (26) | 78 (39.0) | 27 (49.1) | |
| Unknown | 175 (38.1) | 89 (43.6) | 68 (34) | 18 (32.7) | |
| Drugs, n (%) | |||||
| Glucocorticoid | 266/454 (58.6) | 142/203 (69.6) | 25/196 (12.8) | 22 (40) | <0.001 |
| csDMARD | 371/454 (81.7) | 179/203 (88.2) | 150/196 (76.5) | 42 (76.4) | 0.006 |
| Methotrexate | 200/452 (44.2) | 114/203 (56.2) | 50/194 (25.8) | 36 (65.5) | <0.001 |
| Leflunomide | 99/452 (21.9) | 82/202 (40.6) | 7/195 (3.6) | 10 (18.2) | <0.001 |
| Sulfasalazine | 246/453 (54.3) | 81/203 (39.9) | 139/195 (71.3) | 26 (47.3) | <0.001 |
| Hydroxychloroquine | 195/454 (43) | 140/203 (69) | 42/196 (21.4) | 13 (23.6) | <0.001 |
| bDMARD | 135/454 (29.7) | 39/203 (19.2) | 72/196 (36.7) | 24 (43.6) | <0.001 |
| tsDMARD | 3/203 (1.5) | 3/203 (1.5) | N/A | N/A | N/A |
DM: type-2 diabetes mellitus; HT: hypertension; HL: hyperlipidemia; CKD: chronic kidney disease; csDMARD: conventional DMARD; bDMARD: biological DMARD; tsDMARD: targeted synthetic DMARD.
*
Data show median value (lowest–highest).